Lynn C. Hartmann

ORCID: 0000-0002-5931-7876
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Breast Cancer Treatment Studies
  • Ovarian cancer diagnosis and treatment
  • Breast Lesions and Carcinomas
  • BRCA gene mutations in cancer
  • Cancer Genomics and Diagnostics
  • Global Cancer Incidence and Screening
  • Virus-based gene therapy research
  • Cancer Risks and Factors
  • Cancer Cells and Metastasis
  • Genetic factors in colorectal cancer
  • Cancer Immunotherapy and Biomarkers
  • Cancer, Lipids, and Metabolism
  • Cancer-related Molecular Pathways
  • Cancer and Skin Lesions
  • Breast Implant and Reconstruction
  • Endometrial and Cervical Cancer Treatments
  • HER2/EGFR in Cancer Research
  • Estrogen and related hormone effects
  • Cancer Treatment and Pharmacology
  • AI in cancer detection
  • Genomic variations and chromosomal abnormalities
  • Immunotherapy and Immune Responses
  • Nutrition, Genetics, and Disease
  • Cancer Mechanisms and Therapy
  • Immune Cell Function and Interaction

Mayo Clinic
2012-2024

WinnMed
2008-2024

Mayo Clinic in Arizona
2010-2019

Lynn University
2015-2018

Roche (United States)
2018

Mayo Clinic in Florida
2009-2017

University of California, San Francisco
2007-2016

John Wiley & Sons (United States)
2016

Wayne State University
2012-2016

Moffitt Cancer Center
2005-2016

Options for women at high risk breast cancer include surveillance, chemoprevention, and prophylactic mastectomy. The data on the outcomes surveillance mastectomy are incomplete.

10.1056/nejm199901143400201 article EN New England Journal of Medicine 1999-01-14

Benign breast disease is an important risk factor for cancer. We studied a large group of women with benign to obtain reliable estimates this risk.

10.1056/nejmoa044383 article EN New England Journal of Medicine 2005-07-20

In women with a family history of breast cancer, bilateral prophylactic mastectomy is associated decreased risk subsequent cancer approximately 90%. We examined the association between and in at high for who also had mutations BRCA1 BRCA2 genes.We obtained blood samples from 176 214 high-risk participated our previous retrospective cohort study mastectomy. used conformation-sensitive gel electrophoresis direct sequence analysis specimens to identify BRCA2. The carriers' probabilities...

10.1093/jnci/93.21.1633 article EN JNCI Journal of the National Cancer Institute 2001-11-07

Abstract Purpose: Advanced-stage epithelial ovarian cancer has a poor prognosis with long-term survival in less than 30% of patients. When the disease is detected stage I, more 90% patients can be cured by conventional therapy. Screening for early-stage individual serum tumor markers, such as CA125, limited fact that no single marker up-regulated and shed adequate amounts all cancers. Consequently, use multiple markers combination might detect larger fraction Experimental Design: To identify...

10.1158/1078-0432.ccr-03-0409 article EN Clinical Cancer Research 2004-05-15

The breast cancer stem cell (BCSC) hypotheses suggest that is derived from a single tumor-initiating with stem-like properties, but the source of these cells unclear. We previously observed induction an immune response against epithelial led in vivo to T-cell-dependent outgrowth tumor, which had undergone mesenchymal transition (EMT). resulting tumor CD24(-/lo)CD44(+) phenotype, consistent BCSCs. In present study, we found EMT was induced by CD8 T and tumors characteristics BCSCs, including...

10.1158/0008-5472.can-08-3343 article EN Cancer Research 2009-03-11

Molecular classification of high-grade serous ovarian cancer (HGSOC) using transcriptional profiling has proven to be complex and difficult validate across studies. We determined gene expression profiles 174 well-annotated HGSOCs demonstrate prognostic significance the prespecified TCGA Network signatures. Furthermore, we confirm presence four HGSOC subtypes a de novo classification. Survival differed statistically significantly between (log rank, P = .006) was best for immunoreactive-like...

10.1093/jnci/dju249 article EN JNCI Journal of the National Cancer Institute 2014-09-30

Edmonston vaccine strains of measles virus (MV) have shown significant antitumor activity in preclinical models ovarian cancer. We engineered MV to express the marker peptide carcinoembryonic antigen (MV-CEA virus) also permit real-time monitoring viral gene expression tumors clinical setting. Patients with Taxol and platinum-refractory recurrent cancer normal CEA levels were eligible for this phase I trial. Twenty-one patients treated MV-CEA i.p. every 4 weeks up 6 cycles at seven different...

10.1158/0008-5472.can-09-2762 article EN Cancer Research 2010-01-27

Abstract Purpose: PD-0332991 is a selective inhibitor of the CDK4/6 kinases with ability to block retinoblastoma (Rb) phosphorylation in low nanomolar range. Here we investigate role inhibition human ovarian cancer. Experimental Design: We examined effects on proliferation, cell-cycle, apoptosis, and Rb using panel 40 established cancer cell lines. Molecular markers for response prediction, including p16 Rb, were studied gene expression profiling, Western blot, array CGH. Multiple drug...

10.1158/1078-0432.ccr-10-2307 article EN Clinical Cancer Research 2011-01-29

Within the ovarian cancer microenvironment, there are several mechanisms that suppress actions of antitumor immune effectors. Delineating complex microenvironment is an important goal toward developing effective immune-based therapies. A dominant pathway suppression in involves tumor-associated and dendritic cell (DC)-associated B7-H1. The interaction B7-H1 with PD-1 on tumor-infiltrating T cells a widely cited theory involving cancer. Recent studies suggest ligand, programmed death...

10.4049/jimmunol.1100274 article EN The Journal of Immunology 2011-05-07

Abstract Atypical hyperplasia is a high-risk premalignant lesion of the breast, but its biology poorly understood. Many believe that atypical ductal (ADH) direct precursor for low-grade breast cancer, whereas lobular (ALH) serves as risk indicator. These assumptions underlie current clinical recommendations. We tested these by studying characteristics cancers develop in women with ADH or ALH. Using Mayo Benign Breast Disease Cohort, we identified all ALH from 1967 to 2001 and followed them...

10.1158/1940-6207.capr-13-0222 article EN Cancer Prevention Research 2014-01-31

Motivated by the long-recognized value of palpation in detecting breast cancer, we tested feasibility a technique for quantitatively evaluating mechanical properties tissues on basis direct MR imaging visualization acoustic waves.The prototypic elasticity consists device generating shear waves tissue, an imaging-based method propagation these waves, and algorithm processing wave images to generate quantitative depicting tissue stiffness. After tests with tissue-simulating phantom materials...

10.2214/ajr.178.6.1781411 article EN American Journal of Roentgenology 2002-06-01

Abstract Purpose: Epithelial ovarian cancers are thought to arise from flattened epithelial cells that cover the surface or line inclusion cysts. During malignant transformation, different histotypes resemble normal fallopian tube, endometrium, and intestine. This study compares gene expression in serous, endometrioid, clear cell, mucinous with tissues they resemble. Experimental Design: Expression of 63,000 probe sets was measured 50 cancers, 5 pools brushings, mucosal scrapings 4 colon...

10.1158/1078-0432.ccr-04-2509 article EN Clinical Cancer Research 2005-09-01

Quantitation of circulating tumor cells (CTCs) constitutes an emerging tool for the diagnosis and staging cancer, assessment response to therapy, evaluation residual disease after surgery. Unfortunately, no existing technology has sensitivity measure low numbers (<1 CTC per ml whole blood) that characterize minimal levels disease. We present a method, intravital flow cytometry, noninvasively counts rare CTCs in vivo as they through peripheral vasculature. The method involves i.v....

10.1073/pnas.0703875104 article EN Proceedings of the National Academy of Sciences 2007-06-30

PURPOSE: To estimate the efficacy of contralateral prophylactic mastectomy in women with a personal and family history breast cancer. PATIENTS AND METHODS: We followed course 745 first cancer and/or ovarian who underwent at Mayo Clinic between 1960 1993. Family information follow-up were obtained from medical record, study-specific questionnaire, telephone follow-up. Life-tables for cancers, which consider age cancer, current age, type history, used to calculate number cancers expected our...

10.1200/jco.2001.19.19.3938 article EN Journal of Clinical Oncology 2001-10-01

Purpose Atypical hyperplasia is a well-recognized risk factor for breast cancer, conveying an approximately four-fold increased risk. Data regarding long-term absolute and factors stratification are needed. Patients Methods Women with atypical in the Mayo Benign Breast Disease Cohort were identified through pathology review. Subsequent cancers via medical records questionnaire. Relative risks (RRs) estimated using standardized incidence ratios, comparing observed number of those expected...

10.1200/jco.2006.09.0217 article EN Journal of Clinical Oncology 2007-06-12

Background : As women age, the lobules in their breasts undergo involution or regression. We investigated whether lobular with benign breast disease was associated subsequent cancer risk. Methods examined biopsy specimens of 8736 Mayo Benign Breast Disease Cohort from whom samples were taken between January 1, 1967, and December 31, 1991. Median follow-up for outcomes 17 years. classified background tissue as none (0% involuted lobules), partial (1%–74%), complete (≥75%). Subsequent events...

10.1093/jnci/djj439 article EN cc-by-nc JNCI Journal of the National Cancer Institute 2006-11-15

Abstract The high affinity folate receptor is a membrane‐associated glycoprotein that preferentially expressed in cancers of epithelial origin and rarely normal cells. We examined its expression pattern breast cancer, utilizing tissue microarray containing samples from 63 invasive women with divergent clinical outcomes. Thirty‐three comprised the poor outcome group median time to recurrence 1.9 years. Thirty women, good group, were free for minimum 7 years after diagnosis. intensity staining...

10.1002/ijc.22811 article EN International Journal of Cancer 2007-05-08

The use of replicating viruses for cancer therapy (virotherapy) holds much promise. We reported previously that the live attenuated Edmonston B vaccine strain measles virus (MV-Edm) had antineoplastic efficacy against hematological malignancies. In this study, we demonstrate a recombinant MV-Edm, genetically engineered to express an inert soluble marker peptide (MV-hCEA), is potent human epithelial ovarian cells in vitro and vivo. was selectively oncolytic tumor but caused minimal cytopathic...

10.1016/s1525-0016(16)44187-0 article EN cc-by-nc-nd Molecular Therapy 2002-05-01

Breast papillomas may be single or multiple and associated with atypical ductal lobular hyperplasias (ADH/ALH). The risk of breast carcinoma development in patients papillomas, particularly those lesions, is incompletely defined. Fibrocystic lesions were histopathologically classified a benign disease cohort 9155 who underwent biopsy from 1967 to 1991, papilloma assessment 9108. Individuals (N=480) into 4 groups: (SP, N=372), ADH ALH (SP+A, N=54), (>5) (MP, N=41), (MP+A, N=13). Those without...

10.1097/00000478-200606000-00001 article EN The American Journal of Surgical Pathology 2006-05-24

Contralateral prophylactic mastectomy (CPM) is one option for reducing the risk of a second breast cancer in women with personal and family history cancer. Few data are available regarding satisfaction, psychological, social function after CPM. The purpose this research to evaluate women's long-term satisfaction CPM, factors influencing psychological CPM.This was descriptive study all cancer, known be alive, who elected CPM at Mayo Clinic (Rochester, MN) between 1960 1993 (n = 621)....

10.1200/jco.2005.09.233 article EN Journal of Clinical Oncology 2005-10-04

Ovarian cancer is an immune reactive malignancy with a complex suppressive network that blunts successful eradication. This microenvironment may be mediated by recruitment or induction of CD4+ regulatory T cells (Tregs). Our study sought to investigate the association tumor-infiltrating CD4+CD25+FOXP3+ Tregs, and other factors, clinical outcome in serous ovarian patients. We performed immunofluorescence quantification intraepithelial triple positive Tregs (CD4+CD25+FOXP3+), as well...

10.1371/journal.pone.0080063 article EN cc-by PLoS ONE 2013-11-14
Coming Soon ...